To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

October 30, 2025

Study Completion Date

December 30, 2025

Conditions
Digestive System Tumors
Interventions
DRUG

KC1036

KC1036 are administered orally QD or BID in 21-day cycles.

Trial Locations (13)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Unknown

RECRUITING

The first affiliated hospital of bengbu medical college, Bengbu

RECRUITING

Chongqing University Three Gorges Hospital, Chongqing

RECRUITING

Fujian Cancer Hospital, Fujian

RECRUITING

Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Henan

RECRUITING

The First Affiliated Hospital of Xinxiang Medical University, Henan

RECRUITING

Hubei Cancer Hospital, Hubei

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technologe, Hubei

RECRUITING

Shandong Cancer Hospital & Institute, Shandong

RECRUITING

Shanghai Chest Hospital, Shanghai

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen

RECRUITING

Tianjin Medical University Cancer Institute &Hospital, Tianjin

RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang

All Listed Sponsors
lead

Beijing Konruns Pharmaceutical Co., Ltd.

INDUSTRY

NCT05260385 - To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors | Biotech Hunter | Biotech Hunter